Paul Liknaitzky is Head of Clinical Psychedelic Research at the Turner Institute and the Dept of Psychiatry, Monash University. He earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne. He is an Investigator across a number of Australia’s first psychedelic trials, leads Australia’s first clinical psychedelic lab and first applied psychedelic therapist training program, and obtained the first industry funding and partnership for psychedelics in Australia.
Paul's work examines mechanisms of mental illness and treatment development primarily within mood, anxiety and addiction research. He is currently focused on developing a rigorous program of research in psychedelic medicine at Monash University that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms.